

**PRESS RELEASE**

24 March 2022 12:45:00 CET

## **Senzime wins US order with an initial value exceeding 1 million SEK**

**Press release: Uppsala March 24, 2022. Senzime announces today that the company has won an order from a large American academic healthcare system in the upper Midwest. This is a three-hospital facility affiliated with a School of Medicine. The order includes TetraGraph systems with associated disposable sensors at an initial order value exceeding SEK 1 million.**

All operating rooms at the hospitals are equipped with TetraGraph systems. At the same time, the surgical protocol is standardized for patients who receive muscle-blocking drugs with a requirement that these will be monitored. The hospitals annually perform around 11 000 surgeries where these drugs are administered. Future recurrent TetraSens sales will be in addition to the initial order.

*“Most hospitals today continuously and objectively measure critical parameters such as heart rate, blood pressure, oxygen levels and depth of anesthesia. Paralytic management should of course be measured with the same degree of accuracy. It is encouraging to see that more and more hospitals are standardizing objective monitoring of this vital function.”*, says Pia Renaudin, CEO of Senzime

**For further information, please contact:**

---

Pia Renaudin, CEO of Senzime AB  
Phone: +46 (0) 70-813 34 17, email: [pia.renaudin@senzime.com](mailto:pia.renaudin@senzime.com)

### **About Senzime**

---

Senzime is a Swedish medical device company that develops and markets CE- and FDA-cleared monitoring systems for patients undergoing anesthesia. Senzime's employees worldwide are committed to the vision of a world without anesthesia related complications. Six out of ten patients that wake up after surgery are not fully muscle recovered and therefor at risk having critical respiratory complications. The TetraGraph system helps anesthesia providers improve patient care and reduce healthcare costs by digitally and continuously measure the degree of neuromuscular blockade under and after surgery. Senzime operates in the worlds leading markets targeting a market opportunity valued in excess of SEK 15 billion per year. The company's shares are listed on Nasdaq Stockholms main market (ticker SEZI). [www.senzime.com](http://www.senzime.com)

### **Attachments**

---

**[Senzime wins US order with an initial value exceeding 1 million SEK](#)**